Literature DB >> 26763726

An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia.

G Chiriacò1, S Cauci2, G Mazzon1, C Trombetta1.   

Abstract

Concern regarding adverse effects of finasteride is increasing. We aimed to determine the type and frequency of symptoms in men having long-term sexual and non-sexual side effects after finasteride treatment (a condition recently called post-finasteride syndrome, PFS) against androgenetic alopecia (AGA). Subjects were recruited at the Urology Unit of the Trieste University-Hospital, and from a dedicated website. Out of 79 participants, 34% were white Italians, mean age was 33.4 ± 7.60 years, mean duration of finasteride use was 27.3 ± 33.21 months; mean time from finasteride discontinuation was 44.1 ± 34.20 months. Symptoms were investigated by an ad hoc 100 questions' questionnaire, and by validated Arizona Sexual Experience Scale (ASEX) and Aging Male Symptom Scale (AMS) questionnaires. By ASEX questionnaire, 40.5% of participants declared getting and keeping erection very difficult, and 3.8% never achieved; reaching orgasm was declared very difficult by 16.5%, and never achieved by 2.5%. By the ad hoc questionnaire, the most frequent sexual symptoms referred were loss of penis sensitivity (87.3%), decreased ejaculatory force (82.3%), and low penile temperature (78.5%). The most frequent non-sexual symptoms were reduced feeling of life pleasure or emotions (anhedonia) (75.9%); lack of mental concentration (72.2%), and loss of muscle tone/mass (51.9%). We contributed to inform about symptoms of PFS patients; unexpectedly loss of penis sensitivity was more frequent than severe erectile dysfunction and loss of muscle tone/mass was affecting half of the subjects. Further studies are necessary to investigate the pathophysiological and biochemical pathways leading to the post-finasteride syndrome.
© 2016 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  5-alpha-reductase inhibitor; AGA; PFS; Post-finasteride syndrome; benign prostatic hyperplasia; erectile dysfunction; finasteride safety; finasteride side effects; follicle stimulating hormone; free testosterone; loss of libido; luteinizing hormone; male pattern hair loss; sexual dysfunction; testosterone

Mesh:

Substances:

Year:  2016        PMID: 26763726     DOI: 10.1111/andr.12147

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  15 in total

Review 1.  Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome.

Authors:  Raymond Fertig; Jerry Shapiro; Wilma Bergfeld; Antonella Tosti
Journal:  Skin Appendage Disord       Date:  2016-09-23

Review 2.  [Bladder storage and voiding dysfunctions : Side effects of drug therapy].

Authors:  J Wolfesberger; C E Falkensammer; S Madersbacher
Journal:  Urologe A       Date:  2017-04       Impact factor: 0.639

Review 3.  Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?

Authors:  Silvia Giatti; Silvia Diviccaro; Giancarlo Panzica; Roberto Cosimo Melcangi
Journal:  Endocrine       Date:  2018-04-19       Impact factor: 3.633

Review 4.  Safety Profile of Finasteride: Distribution of Adverse Effects According to Structural and Informational Dichotomies of the Mind/Brain.

Authors:  Ion G Motofei; David L Rowland; Mirela Manea; Simona R Georgescu; Ioana Păunică; Ioanel Sinescu
Journal:  Clin Drug Investig       Date:  2017-06       Impact factor: 2.859

Review 5.  The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health.

Authors:  Mohammed A Said; Akanksha Mehta
Journal:  Curr Urol Rep       Date:  2018-06-16       Impact factor: 3.092

Review 6.  Pharmacotherapy considerations in transgender individuals living with human immunodeficiency virus.

Authors:  Melissa E Badowski; Nicholas Britt; Emily C Huesgen; Michelle M Lewis; Misty M Miller; Kathleen Nowak; Elizabeth Sherman; Renata O Smith
Journal:  Pharmacotherapy       Date:  2021-02-27       Impact factor: 4.705

Review 7.  Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.

Authors:  Mark S Nestor; Glynis Ablon; Anita Gade; Haowei Han; Daniel L Fischer
Journal:  J Cosmet Dermatol       Date:  2021-11-06       Impact factor: 2.189

8.  Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia.

Authors:  Sabina Cauci; Giovanni Chiriacò; Erika Cecchin; Giuseppe Toffoli; Serena Xodo; Giuseppe Stinco; Carlo Trombetta
Journal:  Sex Med       Date:  2016-12-23       Impact factor: 2.491

9.  Alterations of gut microbiota composition in post-finasteride patients: a pilot study.

Authors:  F Borgo; A D Macandog; S Diviccaro; E Falvo; S Giatti; G Cavaletti; R C Melcangi
Journal:  J Endocrinol Invest       Date:  2020-09-19       Impact factor: 4.256

10.  Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride.

Authors:  Tina Kiguradze; William H Temps; Steven M Belknap; Paul R Yarnold; John Cashy; Robert E Brannigan; Beatrice Nardone; Giuseppe Micali; Dennis Paul West
Journal:  PeerJ       Date:  2017-03-09       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.